Combined Triple Therapy in Diabetic Retinopathy (DRP)

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this pilot study was to investigate the effects of an intravitreal combination therapy using triamcinolone and bevacizumab in patients with macular edema due to diabetic retinopathy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johann Wolfgang Goethe University Hospital
• Treatments: Bevacizumab; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Diagnosis of diabetic retinopathy

• macular edema more than 200 micron

• vitreous bleeding because of angiography documented NVEs NVDs, based on the definitions of ETDRS

Exclusion Criteria:

• Prior intraocular injection within 4 months

• Core or complete vitrectomy

• History of glaucoma or ocular hypertension

• Presence of iris neovascularization

• Significant media opacity

• Monocularity and pregnancy